| Literature DB >> 28251071 |
Phedy Phedy1, H Dilogo Ismail1, Charles Hoo1, Yoshi P Djaja1.
Abstract
AIM: To determine whether cemented, cementless, or hybrid implant was superior to the other in terms of survival rate.Entities:
Keywords: Cemented; Cementless; Hybrid; Implant survival; Meta-analysis; Total hip replacement
Year: 2017 PMID: 28251071 PMCID: PMC5314150 DOI: 10.5312/wjo.v8.i2.192
Source DB: PubMed Journal: World J Orthop ISSN: 2218-5836
Figure 1Study selection algorithm.
Characteristics of the included studies
| Bjørgul et al[ | 65 to 66 | 14 | Osteoarthritis (most) | 3rd | Cemented ( | Hybrid ( | direct lateral | |
| Chandran et al[ | 64.5 to 65.5 | 14 | primary Osteoarthritis | 2nd | Cemented ( | Cementless ( | anterolateral | |
| Corten et al[ | 64 (mean) | 19.5 | primary Osteoarthritis | 2nd | Cemented ( | Cementless ( | direct lateral | |
| Kim et al[ | 43.4 to 46.8 | 18.4 | Avascular necrosis (most) | 3rd | Hybrid ( | Cementless ( | ND | May overlap with Kim et al[ |
| McCombe et al[ | 67.3 | 6.5 to 8 | Primary OA (most) | 2nd | Cemented ( | Hybric ( | posterolateral | |
| Berend et al[ | 67.1 | 6.8 | Osteoarthritis (most) | ND | Cemented ( | Cementless ( | anterolateral and posterior | |
| Clohisy et al[ | 61 to 62 | 10 to 11 | Osteoarthritis | 2nd | Cemented ( | Hybrid ( | posterolateral | |
| Emerson et al[ | 55 to 70 | 6.7 to 7.2 | Osteoarthritis (most) | 3rd | Hybrid ( | Cementless ( | anterolateral | |
| Hartofilakidis et al[ | 39.6 to 45.4 | 12.4 to 15.4 | Osteoarthrosis secondary to congenital hip disease (most) | 2nd | Cemented ( | Hybric ( | lateral transtrochanteric | |
| Kim et al[ | 64.6 | 17.3 | Avascular necrosis | 3rd | Hybrid ( | Cementless ( | ND | May overlap with et al[ |
| Pospula et al[ | 46.7 to 53.7 | 3 to 5 | Avascular necrosis (most) | ND | Cemented ( | Cementless ( | cemented posterolateral cementless transgluteal | |
| Van Stralen et al[ | 69.5 | 2.5 | Primary OA (most) | Cemented ( | Cementless ( | posterior | ||
| Thomason et al[ | 54 | 7.4 | Rheumatoid arthritis | ND | Hybrid ( | Cementless ( | posterior | |
| Zimmerman et al[ | 74.9 | 1 | Osteoarthritis | ND | Hybrid ( | Cementless ( | anterolateral, posterior | |
| Conroy et al[ | Any | 5 | Osteoarthritis | ND | Cemented ( | ND | ||
| Cementless ( | ||||||||
| Dale et al[ | Any | 0 to 20 | Osteoarthritis (most) | ND | Cemented ( | Cementless ( | ND | May overlap with study of et al[ |
| Engesaeter et al[ | Any | 0 to 16 | Primary Osteoarthritis | ND | Cemented ( | Cementless ( | ND | May overlap with et al[ |
| Eskelinen et al[ | < 55 | 0 to 24 | Rheumatoid arthritis | ND | Cemented ( | Cementless ( | ND | |
| Hailer et al[ | Any | 15 | Osteoarthritis (most) | ND | Cemented ( | Cementless ( | ND | |
| Hooper et al[ | Any | 7 | ND | ND | Cemented ( | ND | ||
| Cementless ( | ||||||||
| Lucht et al[ | Any | 4 | ND | Cemented ( | ND | |||
| Cementless ( | ||||||||
| Mäkelä et al[ | > 55 | 15 | Osteoarthritis | ND | Cemented ( | Cementless ( | ND | |
| Mäkelä et al[ | 63 to 69 (> 55) | 15 | Rheumatoid arthritis | ND | Cemented ( | Cementless ( | ND | |
| Mäkelä et al[ | < 55 | 15 | Osteoarthritis | ND | Cemented ( | Cementless ( | ND | |
| Malchau et al[ | All | 8 | Osteoarthritis (most) | ND | Cemented ( | Cementless ( | ND | |
| Pedersen et al[ | Any | 0 to 14 | Osteoarthritis (most) | ND | Cemented ( | ND | ||
| Hybrid ( | ||||||||
| Roberts et al[ | All | ND | ND | ND | Cemented ( | Cementless ( | ND | |
Summary of finding comparing cemented and cementless total hip replacement
| Revision of any component due to any reason - RCT Follow-up: 14 to 19.5 yr | Study population | RR 1.43 (1 to 2.04) | 452 (2 studies) | ++-- low | ||
| 165 per 1000 | 235 per 1000 (165 to 336) | |||||
| Moderate | ||||||
| 156 per 1000 | 223 per 1000 (156 to 318) | |||||
| Revision of any component due to any reason - Register or Cohort of register Follow-up: 0 to 24 yr | Study population | RR 0.46 (0.45 to 0.47) | 518774 (10 studies) | +--- very low | ||
| 99 per 1000 | 46 per 1000 (45 to 47) | |||||
| Moderate | ||||||
| 122 per 1000 | 56 per 1000 (55 to 57) | |||||
| Revision of any component due to any reason - All types of study Follow-up: 0 to 24 yr | Study population | RR 0.47 (0.45 to 0.48) | 521757 (13 studies) | +--- very low | ||
| 99 per 1000 | 46 per 1000 (44 to 47) | |||||
| Moderate | ||||||
| 106 per 1000 | 50 per 1000 (48 to 51) | |||||
| Revision of any component due to aseptic loosening - RCT Follow-up: 14 to 19.5 yr | Study population | RR 2 (1.29 to 3.1) | 452 (2 studies) | +++- moderate | ||
| 104 per 1000 | 208 per 1000 (134 to 322) | |||||
| Moderate | ||||||
| 97 per 1000 | 194 per 1000 (125 to 301) | |||||
| Revision of any component due to aseptic loosening - Register or Cohort of register Follow-up: 0 to 24 yr | Study population | RR 0.88 (0.83 to 0.94) | 255779 (6 studies) | +--- very low | ||
| 47 per 1000 | 41 per 1000 (39 to 44) | |||||
| Moderate | ||||||
| 48 per 1000 | 42 per 1000 (40 to 45) | |||||
| Revision of any component due to aseptic loosening - All types of study Follow-up: 0 to 24 yr | Study population | RR 0.9 (0.84 to 0.95) | 256231 (8 studies) | +--- very low | ||
| 47 per 1000 | 43 per 1000 (40 to 45) | |||||
| Moderate | ||||||
| 48 per 1000 | 43 per 1000 (40 to 46) | |||||
| Revision of any component due to infection - Register or Cohort of register Follow-up: 0 to 20 yr | Study population | RR 1.27 (1.04 to 1.55) | 382433 (6 studies) | +--- very low | ||
| 5 per 1000 | 6 per 1000 (5 to 7) | |||||
| Moderate | ||||||
| 4 per 1000 | 5 per 1000 (4 to 6) | |||||
| Revision of any component due to infection - All types of study Follow-up: 0 to 20 yr | Study population | RR 1.29 (1.06 to 1.57) | 382683 (7 studies) | +--- very low | ||
| 5 per 1000 | 6 per 1000 (5 to 7) | |||||
| Moderate | ||||||
| 4 per 1000 | 5 per 1000 (4 to 6) | |||||
| Dislocation of any component - Cohort Follow-up: 2.5 to 5 yr | Study population | RR 0.69 (0.29 to 1.67) | 1066 (2 studies) | +--- very low | ||
| 30 per 1000 | 21 per 1000 (9 to 50) | |||||
| Moderate | ||||||
| 30 per 1000 | 21 per 1000 (9 to 50) | |||||
| Dislocation of any component - Register or Cohort of register Follow-up: 5 to 15 yr | Study population | RR 0.69 (0.59 to 0.8) | 254786 (6 studies) | +--- very low | ||
| 6 per 1000 | 4 per 1000 (4 to 5) | |||||
| Moderate | ||||||
| 13 per 1000 | 9 per 1000 (8 to 10) | |||||
| Dislocation of any component - All types of study Follow-up: 2.5 to 15 yr | Study population | RR 0.69 (0.6 to 0.79) | 255852 (8 studies) | +--- very low | ||
| 6 per 1000 | 4 per 1000 (4 to 5) | |||||
| Moderate | ||||||
| 14 per 1000 | 10 per 1000 Ta(8 to 11) | |||||
CI: Confidence interval; RR: Risk ratio; GRADE Working Group grades of evidence; High quality: Further research is very unlikely to change our confidence in the estimate of effect; moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; very low quality: We are very uncertain about the estimate.
95% confidence interval around the pooled or best estimate of effect includes both (1) no effect and (2) appreciable benefit or appreciable harm (> 25%);
No explanation was provided;
Unexplained heterogeneity;
Indirect studies from registers;
Overall result from all types of study;
High heterogeneity, explained by meta-regression;
The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%CI).
Figure 2Forest plot of comparison: Cemented vs cementless: Revision of any component due to any reason.
Figure 3Forest plot of comparison: Cemented vs cementless: Revision of any component due to aseptic loosening.
Figure 4Forest plot of comparison: Cemented vs cementless: Revision of any component due to infection.
Figure 5Forest plot of comparison: Cemented vs cementless: Dislocation of any component.
Figure 6Forest plot of comparison: Cemented vs hybrid: Revision of any component due to any reason.
Figure 7Forest plot of comparison: Cemented vs hybrid: Revision of any component due to aseptic loosening.
Figure 8Forest plot of comparison: Cemented vs hybrid: Revision of any component due to infection.
Figure 9Forest plot of comparison: Cemented vs hybrid: Dislocation of any component.
Figure 10Forest plot of comparison: Cementless vs hybrid: Revision of any component due to any reason.
Figure 11Forest plot of comparison: Cementless vs hybrid: Revision of any component due to infection.
Figure 12Forest plot of comparison: Cementless vs hybrid: Revision of any component due to infection.
Figure 13Forest plot of comparison: Cementless vs hybrid: Dislocation of any component.
Figure 14Funnel plot of comparison of revision of any component (A) cementless vs cementless; (B) cemented vs hybrid; (C) cementless vs hybrid.
Summary of finding table comparing cemented to hybrid total hip replacement
| Revision of any component due to any reason - RCT Follow-up: 6.5 to 14 yr | Study population | RR 0.73 (0.47 to 1.13) | 402 (2 studies) | +--- very low | ||
| 187 per 1000 | 136 per 1000 (88 to 211) | |||||
| Moderate | ||||||
| 177 per 1000 | 129 per 1000 (83 to 200) | |||||
| Revision of any component due to any reason - Register or Cohort of register Follow-up: 4 to 7 yr | Study population | RR 0.82 (0.76 to 0.89) | 76746 (3 studies) | +--- very low | ||
| 30 per 1000 | 24 per 1000 (23 to 26) | |||||
| Moderate | ||||||
| 31 per 1000 | 25 per 1000 (24 to 28) | |||||
| Revision of any component due to any reason - All types of study Follow-up: 4 to 15.4 yr | Study population | RR 0.82 (0.76 to 0.89) | 77265 (6 studies) | +--- very low | ||
| 31 per 1000 | 25 per 1000 (23 to 27) | |||||
| Moderate | ||||||
| 104 per 1000 | 85 per 1000 (79 to 93) | |||||
| Revision of any component due to aseptic loosening - All types of study Follow-up: 6.5 to 15.4 yr | Study population | RR 2.65 (1.14 to 6.17) | 519 (3 studies) | +--- very low | ||
| 23 per 1000 | 62 per 1000 (27 to 145) | |||||
| Moderate | ||||||
| 0 per 1000 | 0 per 1000 (0 to 0) | |||||
| Revision of any component due to infection - Register or Cohort of register Follow-up: 0 to 14 yr | Study population | Not estimable | 86389 (2 studies) | +--- very low | ||
| 7 per 1000 | 0 per 1000 (0 to 0) | |||||
| Moderate | ||||||
| Revision of any component due to infection - All types of study Follow-up: 0 to 14 yr | Study population | RR 0.98 | 86881 | +--- | ||
| 7 per 1000 | 7 per 1000 (5 to 10) | (0.7 to 1.38) | (5 studies) | very low | ||
| Moderate | ||||||
| 2 per 1000 | 2 per 1000 (1 to 3) | |||||
| Dislocation of any component - Register of Cohort of register Follow-up: 5 to 7 yr | Study population | RR 0.68 (0.57 to 0.8) | 60584 (2 studies) | +--- very low | ||
| 11 per 1000 | 7 per 1000 (6 to 9) | |||||
| Moderate | ||||||
| 11 per 1000 | 7 per 1000 (6 to 9) | |||||
| Dislocation of any component - All types of study Follow-up: 5 to 14 yr | Study population | RR 0.67 (0.57 to 0.79) | 60824 (3 studies) | +--- very low | ||
| 11 per 1000 | 7 per 1000 (6 to 9) | |||||
| Moderate | ||||||
| 14 per 1000 | 9 per 1000 (8 to 11) | |||||
CI: Confidence interval; RR: Risk ratio; GRADE Working Group grades of evidence; High quality: Further research is very unlikely to change our confidence in the estimate of effect; moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; very low quality: We are very uncertain about the estimate.
95% confidence interval around the pooled or best estimate of effect includes both (1) no effect and (2) appreciable benefit or appreciable harm (> 25%);
No explanation was provided;
Unexplained heterogeneity;
Indirect studies from registers;
Overall result from all types of study;
The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%CI).
Summary of finding table comparing hybrid and cementless total hip replacement
| Revision of any component due to any reason - Cohort Follow-up: 1 to 17.3 yr | Study population | RR 1.03 (0.69 to 1.54) | 706 (4 studies) | +--- very low | ||
| 105 per 1000 | 108 per 1000 (72 to 161) | |||||
| Moderate | ||||||
| 106 per 1000 | 109 per 1000 (73 to 163) | |||||
| Revision of any component due to any reason - Register or Cohort of register Follow-up: 4 to 7 yr | Study population | RR 0.69 (0.64 to 0.74) | 81635 (3 studies) | +--- very low | ||
| 33 per 1000 | 23 per 1000 (21 to 25) | |||||
| Moderate | ||||||
| 39 per 1000 | 27 per 1000 (25 to 29) | |||||
| Revision of any component due to any reason - All types of study Follow-up: 1 to 18.4 yr | Study population | RR 0.7 (0.65 to 0.75) | 82560 (8 studies) | +--- very low | ||
| 34 per 1000 | 24 per 1000 (22 to 26) | |||||
| Moderate | ||||||
| 116 per 1000 | 81 per 1000 (75 to 87) | |||||
| Revision of any component due to aseptic loosening - Cohort Follow-up: 6.7 to 17.3 yr | Study population | RR 0.84 (0.47 to 1.51) | 447 (3 studies) | +--- very low | ||
| 76 per 1000 | 64 per 1000 (36 to 115) | |||||
| Moderate | ||||||
| 20 per 1000 | 17 per 1000 (9 to 30) | |||||
| Revision of any component due to aseptic loosening - All types of study Follow-up: 6.7 to 17.3 yr | Study population | RR 0.85 (0.49 to 1.5) | 666 (4 studies) | +--- very low | ||
| 58 per 1000 | 49 per 1000 (28 to 86) | |||||
| Moderate | ||||||
| 19 per 1000 | 16 per 1000 (9 to 28) | |||||
| Revision of any component due to infection - Register or Cohort of register Follow-up: 0 to 14 yr | Study population | Not estimable | 72197 (2 studies) | +--- very low | ||
| 4 per 1000 | 0 per 1000 (0 to 0) | |||||
| Moderate | ||||||
| Revision of any component due to infection - All types of study Follow-up: 0 to 18.4 yr | Study population | RR 1.47 (0.93 to 2.34) | 72863 (5 studies) | +--- very low | ||
| 4 per 1000 | 6 per 1000 (4 to 10) | |||||
| Moderate | ||||||
| 0 per 1000 | 0 per 1000 (0 to 0) | |||||
| Dislocation of any component - Register or Cohort of register Follow-up: 5 to 7 yr | Study population | RR 1.12 (0.97 to 1.3) | 75114 (2 studies) | +--- very low | ||
| 9 per 1000 | 10 per 1000 (9 to 11) | |||||
| Moderate | ||||||
| 10 per 1000 | 11 per 1000 (10 to 13) | |||||
| Dislocation of any component - All types of study Follow-up: 5 to 18.4 yr | Study population | RR 1.13 (0.98 to 1.3) | 75333 (3 studies) | +--- very low | ||
| 9 per 1000 | 10 per 1000 (9 to 11) | |||||
| Moderate | ||||||
| 9 per 1000 | 10 per 1000 (9 to 12) | |||||
CI: Confidence interval; RR: Risk ratio; GRADE Working Group grades of evidence; High quality: Further research is very unlikely to change our confidence in the estimate of effect; moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate; low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate; very low quality: We are very uncertain about the estimate.
95% confidence interval around the pooled or best estimate of effect includes both (1) no effect and (2) appreciable benefit or appreciable harm (> 25%);
No explanation was provided;
Unexplained heterogeneity;
Indirect studies from registers;
Overall result from all types of study;
High heterogeneity, explained by meta-regression;
The basis for the assumed risk (e.g., the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95%CI).